CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 265 target
Drug / intervention
SHR-1210 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03827837
NCT03827837Phase 2Unknown
CompareCT.gov

Famitinib Malate Plus Anti-PD1 Therapy (SHR-1210) in Advanced Renal Cell Carcinoma, Urothelial Carcinoma, Advanced Cervical Cancer, Relapse Ovarian Cancer, Endometrial Cancer: Multi-institutional, Open-label, Phase 2 Trial

Jiangsu HengRui Medicine Co., Ltd.·interventional·Posted Feb 4, 2019·Updated Jul 1, 2022

In Brief

A Phase 2 clinical trial evaluating SHR-1210 and Famitinib for Renal Cell Carcinoma and 4 related conditions. Targeting 265 participants across 1 site.

Detailed Summary

Phase II multi-chort, adaptive two-stage, open label, nonrandomized study. The aim of our study is to evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210(Camrelizumab) in combination with a small-molecule multikinase inhibitor Famitinib in subjects with advanced RCC/UC/CC/EC and recurrent OC. chort1: Renal Cell Carcinoma (RCC) chort2: Urothelial Carcinoma(UC) chort3: Ovarian Cancer (OC) chort4: Cervical Cancer (CC) chort5: Endometrial Cancer (EC)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent, Endometrial Cancer
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
20192020202120222023202420252026
First PostedFeb 4, 2019
Enrollment StartJan 23, 2019
Primary CompletionDec 1, 2022
TodayJul 1, 2026
Enrollment to primary: 3.9 yearsPosted 7.4 years ago

Interventions

SHR-1210biological

SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody

Famitinibdrug

a small-molecule multikinase inhibitor